Isomorphic Labs Prepares to Launch Human Trials for AI-Designed Drugs, CEO Colin Murdoch Says

Google DeepMind's AI arm, Isomorphic Labs, is gearing up for its first human trials of AI-designed drugs. Born from DeepMind's AlphaFold breakthrough, the company aims to design medicines faster, cheaper, and more accurately. The trials will test AI-designed drugs for cancer, with the goal of eventually curing all diseases. Isomorphic Labs has raised $600 million and signed collaborations with pharma giants Novartis and Eli Lilly to build a "world-class drug design engine."